Foresite Capital Management VI LLC bought $533K of Alumis (ALMS)
Executed Nov 21 2025, disclosed Nov 25 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Nov 25 2025), the stock returned +54.7% (delay-adjusted); from the execution session (Nov 21 2025), +63.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Foresite Capital Management VI LLC (10% owner) filed 3 Form 4 reports as a reporting entity in the trailing twelve months (3 purchases, 0 sales), most often in Alumis Inc. (ALMS). Across 3 priced purchase filings, the average 21-session return was +71.1% from execution and +54.8% from disclosure (delay-adjusted; derived). The largest single filing was $7.0M of ALMS (411,764 sh across 2 lots, as filed), executed Jan 8.
Healthcare · Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disor…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→411,764 sh across 2 lots
Exec Jan 8
Filed Jan 12 · 9:58 PM ET ALMSPURCHASE Alumis Inc. $3.1M
507,874 sh across 4 lots
Exec Nov 17 2025
Filed Nov 19 2025 · 8:52 PM ET